Document is current

Article History

Received: 25 July 2025

Accepted: 27 August 2025

First Online: 18 October 2025

Competing interests

: A.S. reported institutional research grants from MSD during the conduct of the study and outside the submitted work from BeOne, BMS, GBA-Innovationsfond, Deutsche Krebshilfe, Exelixis, Jazz, MerckKgA, MSD, Servier, Pierre Fabre, Takeda and institutional fees for advisory boards or lectures from Amgen, Astellas, AstraZeneca, BeOne, BMS, Daiichi Sankyo, Jazz, Merck, MSD, Roche, Sanofi, Servier, Taiho and Takeda. E.G. reported personal fees from BMS and MSD during the conduct of the study; and personal fees from Servier, Roche, and Sanofi outside the submitted work. T.J.E. reported grants from Servier, nonfinancial support from Ipsen, and personal fees from MSD, BMS, AstraZeneca, Roche, Eisai, Pierre Fabre, Merck Serono and Bayer outside the submitted work. S.-E.A.-B. reported grants from BMS, MSD, Sanofi, Ipsen, Roche Hospira, Lilly, Vifor Pharma, Hospira, AstraZeneca, Immutep and Eurozyto and personal fees from Lilly, AstraZeneca and BMS outside the submitted work. M.B. reported grants from MSD covering the translational studies in this trial during the conduct of the study. J.T. declared travel support from BeOne and research support from Takeda and Jazz outside of the current work. The other authors declare no competing interests.